Pembrolizumab and Exemestane/ Leuprolide in Premenopausal HR+/ HER2- Locally Advanced or Metastatic Breast Cancer (PEER)

A Pilot Study of Pembrolizumab and Exemestane/ Leuprolide in Premenopausal Hormone Receptor Positive/ HER2 Negative Locally Advanced or Metastatic Breast Cancer

This is an open-label, single-arm, multicenter, pilot study of pembrolizumab, exemestane, and leuprolide for subjects being resistant for front-line hormonal therapy for inoperable locally advanced or metastatic hormonal receptor positive (HR+)/ Human epidermal growth factor receptor 2 (HER2) negative breast cancer. All the patients will be included in the final tolerability and preliminary efficacy analysis. The efficacy objectives including PFS, overall response rate (ORR), clinical benefit rate (CBR), and duration of response (DOR). Adverse effects will be recorded according to CTCAE v4.0.

Study Overview

• Status: Terminated
• Conditions: Premenopausal Breast Cancer
• Intervention / Treatment: Drug: Pembrolizumab/ Exemestane/ Leuprolide

• Study Type: Interventional
• Enrollment (Actual): 16
• Phase: Phase 2; Phase 1

Contacts and Locations

• Study Contact: Name: Yen-Shen Lu, MD, PhD; Phone Number: +886-2-23123456; Email: yslu@ntu.edu.tw

Study Locations

• Taiwan
  • Taipei, Taiwan, 100
    • National Taiwan University Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 20 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: Female

Description

Inclusion Criteria:

1. Be a female adult aged more than 20-year-old at the time of informed consent.
2. Have histologically confirmed ER positive (defined as ≥1%) and/ or PR positive (defined as ≥1%) breast cancer.
3. Have histologically confirmed HER2-negative breast cancer as defined by IHC ≤ 2+, and/or FISH negative.
4. Have radiological or objective evidence of inoperable locally advanced or metastatic breast cancer.

5. Be premenopausal or peri-menopausal. Premenopausal or peri-menopausal status is defined as below:

   • Last menstrual period within the last 12 months OR
   • With a plasma estradiol ≥10pg/ml and FSH ≤40IU/L

6. Be resistant to front line hormonal therapy, as defined as one of the following criteria:

   • Have become inoperable locally advanced or metastatic disease within one year of adjuvant hormonal therapy.
   • Fail at least 2 line of prior hormonal therapy for locally advanced or metastatic breast cancer.
   • Have history of disease progressed within 6 months during 1st line hormone therapy for locally advanced or metastatic disease.
7. Prior exemestane usage is allowed, but the patient number is limited to ≤10 patients.
8. Have archival primary tumor specimen from diagnosis.
9. Have metastatic tumor specimen before enrollment.
10. Have measurable disease as per RECIST 1.1 or non-measurable lytic or mixed (lytic + blastic) bone lesions in the absence of measurable disease.
11. Have ECOG performance status 0 or 1 assessed within 10 days of treatment initiation.
12. Have adequate bone marrow and organ function.
13. For women of childbearing potential must have a negative serum beta-hCG or urine pregnancy test obtained within 3 days before starting treatment.
14. Female subjects of childbearing potential must be willing to use an adequate method of contraception as outlined in Section - Contraception, for the course of the study through 120 days after the last dose of study medication.
15. Be able to comply with study procedures and sign an informed consent.

Exclusion Criteria:

1. Is currently participating in an investigational agent study.
2. Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 1 week prior to the first dose of study treatment. Physiological steroid replacement is allowed.
3. Has had chemotherapy within 2 weeks prior to the first dose of study treatment or has not recovered from side effects (i.e. Grade 1 at baseline) except alopecia related to prior therapy.
4. Is a hepatitis B or C carrier.
5. Has concurrent malignancy other than non-melanoma skin cancer.
6. Is not able to undergo metastatic tumor biopsy.
7. Has an active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Note: Replacement therapy (i.e. thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.
8. Has a history of (non-infectious) pneumonitis that required steroids, or current pneumonitis.
9. Has an active infection requiring systemic therapy.
10. Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.
11. Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.
12. Has received prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2 agent or with an agent directed to another co-inhibitory T-cell receptor (e.g. CTLA-4, OX-40, CD137) or has previously participated in Merck pembrolizumab clinical trials.
13. Has received a live-virus vaccination within 30 days of planned treatment start. Seasonal flu vaccines that do not contain live virus are permitted.
14. Is lactating, pregnant, or unwilling to employ birth control methods during the study.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Pembrolizumab/ Exemestane/ Leuprolide; Dose level 1 (Pembrolizumab 150 mg IV Q2W); Dose level -1 (Pembrolizumab 100 mg IV Q2W); Dose level -2 (Pembrolizumab 50 mg IV Q2W) Combination with Exemestane 25 mg PO QD, and Leuprolide 3.75 mg SC Q4W	Drug: Pembrolizumab/ Exemestane/ Leuprolide; Dose level 1 (Pembrolizumab 150 mg IV Q2W); Dose level -1 (Pembrolizumab 100 mg IV Q2W); Dose level -2 (Pembrolizumab 50 mg IV Q2W) Combination with Exemestane 25 mg PO QD, and Leuprolide 3.75 mg SC Q4W

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
The PFS rate at 8 months	To estimate the efficacy of the combination of pembrolizumab and exemestane/ leuprolide in premenopausal with hormone receptor positive/ HER2 negative locally advanced or metastatic breast cancer patients, as defined by PFS rate at 8 months.	28 months

Secondary Outcome Measures

Outcome Measure	Time Frame
Number of participants with treatment-related adverse events as assessed by CTCAE v4.0	28 months
The PFS based on RECIST 1.1	28 months
The overall response rate (ORR) based on RECIST 1.1	28 months
The clinical benefit rate (CBR) based on RECIST 1.1	28 months
The duration of overall response (DOR) based on RECIST 1.1	28 months

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
The correlation of potential predictive markers with the efficacy of the combination of pembrolizumab and exemestane/ leuprolide	The predictive markers including: PD-L1 expression in primary and metastatic tumors, as well as in circulating tumor cells; tumor infiltrating lymphocytes in primary and metastatic tumors; mutational load and neoantigens in metastatic tumors; change in cancer immune response profile between primary and metastatic tumors; luminal type change by PAM50 in primary and metastatic tumors	28 months

Collaborators and Investigators

• Sponsor: National Taiwan University Hospital
• Collaborators: Merck Sharp & Dohme LLC

Study record dates

Study Major Dates

• Study Start (Actual): September 15, 2017
• Primary Completion (Actual): August 16, 2022
• Study Completion (Actual): August 16, 2022

Study Registration Dates

• First Submitted: December 1, 2016
• First Submitted That Met QC Criteria: December 8, 2016
• First Posted (Estimate): December 13, 2016

Study Record Updates

• Last Update Posted (Estimate): February 22, 2023
• Last Update Submitted That Met QC Criteria: February 20, 2023
• Last Verified: February 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Skin Diseases; Neoplasms; Neoplasms by Site; Breast Diseases; Breast Neoplasms; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Enzyme Inhibitors; Antineoplastic Agents; Hormones, Hormone Substitutes, and Hormone Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Immunological; Hormone Antagonists; Aromatase Inhibitors; Steroid Synthesis Inhibitors; Estrogen Antagonists; Reproductive Control Agents; Fertility Agents, Female; Fertility Agents; Leuprolide; Pembrolizumab; Exemestane
• Other Study ID Numbers: 201610003MIFA

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No